- Home
- BLTE vs SDGR Comparison
BLTE vs SDGR Comparison
Compare BLTE & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- SDGR
- Stock Information
- Founded
- BLTE 2018
- SDGR 1990
- Country
- BLTE United States
- SDGR United States
- Employees
- BLTE N/A
- SDGR N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- BLTE Health Care
- SDGR Health Care
- Exchange
- BLTE Nasdaq
- SDGR Nasdaq
- Market Cap
- BLTE 1.7B
- SDGR 1.8B
- IPO Year
- BLTE 2022
- SDGR 2020
- Fundamental
- Price
- BLTE $57.37
- SDGR $22.64
- Analyst Decision
- BLTE Strong Buy
- SDGR Buy
- Analyst Count
- BLTE 4
- SDGR 9
- Target Price
- BLTE $96.33
- SDGR $32.11
- AVG Volume (30 Days)
- BLTE 27.8K
- SDGR 1.0M
- Earning Date
- BLTE 03-10-2025
- SDGR 02-26-2025
- Dividend Yield
- BLTE N/A
- SDGR N/A
- EPS Growth
- BLTE N/A
- SDGR N/A
- EPS
- BLTE N/A
- SDGR N/A
- Revenue
- BLTE N/A
- SDGR $193,348,000.00
- Revenue This Year
- BLTE N/A
- SDGR N/A
- Revenue Next Year
- BLTE N/A
- SDGR $31.43
- P/E Ratio
- BLTE N/A
- SDGR N/A
- Revenue Growth
- BLTE N/A
- SDGR N/A
- 52 Week Low
- BLTE $31.01
- SDGR $16.67
- 52 Week High
- BLTE $86.53
- SDGR $33.63
- Technical
- Relative Strength Index (RSI)
- BLTE 48.86
- SDGR 43.67
- Support Level
- BLTE $55.90
- SDGR $23.14
- Resistance Level
- BLTE $58.54
- SDGR $28.47
- Average True Range (ATR)
- BLTE 2.70
- SDGR 1.60
- MACD
- BLTE 0.24
- SDGR -0.34
- Stochastic Oscillator
- BLTE 52.14
- SDGR 9.19
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.